A drug that can extend the life of patients with inoperable skin cancer has been approved for use by the NHS in Scotland.
The decision by the Scottish Medicines Consortium (SMC) brings Scotland in line with England, where patients have already been able to get the drug Vemurafenib.
Up until now the only option for those in Scotland with metastatic melanoma, where their cancer has spread, has been chemotherapy.
But research suggests Vemurafenib could extend the life of such patients, with a trial showing those taking the drug lived for 13.6 months compared to 9.7 months for those given chemotherapy.
The medication - which is also known as Zelboraf - targets the activity of the faulty BRAF V600 gene, which is present in half of all patients with inoperable metastatic melanoma.
The SMC had turned down the drug for use by the NHS when it considered it last September, but the treatment has been available for patients in England from March 2012, first via the cancer drugs fund and then after it was approved by the National Institute for Health and Care Excellence (Nice), the body south of the border which considers such issues.
Dr Marianne Nicolson, consultant medical oncologist from Aberdeen Royal Infirmary, welcomed the decision to approve the drug, saying: "Advanced melanoma is an aggressive cancer affecting many patients who are in the prime of their lives.
"The decision by the SMC to allow NHS clinicians in Scotland to prescribe Vemurafenib for BRAF mutant melanoma patients will enable our patients to benefit from the welcome, long awaited breakthrough in the management of advanced metastatic melanoma."
Cancer charities also welcomed the decision, with Leigh Smith, chair of Melanoma Action and Support Scotland charity (MASScot) saying she was "delighted" the drug had been approved.
She added: "We are aware from trials in which Scottish patients participated that Zelboraf can greatly improve the quality of life as well as extending it. Thank you to all involved in development, clinical trials and in particular those brave patients who participated in trials."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article